The stratification of gliomas based on the presence or absence of mutations in IDH1 or IDH2 has represented a major advancement in the understanding of glioma biology and has improved diagnostic and prognostic accuracy, to the extent that this criterion alone is sufficient to discriminate between astrocytomas and glioblastomas. This evidence concerns the gene IDH2 and astrocytoma (excluding glioblastoma).